Exact Therapeutics AS (EXTX) - Total Assets
Based on the latest financial reports, Exact Therapeutics AS (EXTX) holds total assets worth Nkr153.20 Million NOK (≈ $16.12 Million USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Exact Therapeutics AS - Total Assets Trend (2017–2024)
This chart illustrates how Exact Therapeutics AS's total assets have evolved over time, based on quarterly financial data. Also see Exact Therapeutics AS (EXTX) market capitalisation for the company's overall valuation and market capitalisation.
Exact Therapeutics AS - Asset Composition Analysis
Current Asset Composition (December 2024)
Exact Therapeutics AS's total assets of Nkr153.20 Million consist of 87.0% current assets and 13.1% non-current assets. Review total liabilities of Exact Therapeutics AS to assess the company's total debt and financial obligations.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr99.54 Million | 64.0% |
| Accounts Receivable | Nkr0.00 | 0.0% |
| Inventory | Nkr0.00 | 0.0% |
| Property, Plant & Equipment | Nkr4.81 Million | 3.1% |
| Intangible Assets | Nkr0.00 | 0.0% |
| Goodwill | Nkr0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Exact Therapeutics AS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Exact Therapeutics AS (EXTX) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Exact Therapeutics AS's current assets represent 87.0% of total assets in 2024, a decrease from 98.5% in 2017.
- Cash Position: Cash and equivalents constituted 64.0% of total assets in 2024, down from 75.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is cash and equivalents at 64.0% of total assets.
Exact Therapeutics AS Competitors by Total Assets
Key competitors of Exact Therapeutics AS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Exact Therapeutics AS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.54 | 3.61 | 16.60 |
| Quick Ratio | 3.54 | 3.61 | 16.60 |
| Cash Ratio | 2.65 | 3.00 | 0.00 |
| Working Capital | Nkr95.61 Million | Nkr40.41 Million | Nkr130.04 Million |
Exact Therapeutics AS - Advanced Valuation Insights
This section examines the relationship between Exact Therapeutics AS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.76 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 149.8% |
| Total Assets | Nkr153.20 Million |
| Market Capitalization | $5.26 Million USD |
Valuation Analysis
Below Book Valuation: The market values Exact Therapeutics AS's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Exact Therapeutics AS's assets grew by 149.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Exact Therapeutics AS (2017–2024)
The table below shows the annual total assets of Exact Therapeutics AS from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr153.20 Million ≈ $16.12 Million |
+149.84% |
| 2023-12-31 | Nkr61.32 Million ≈ $6.45 Million |
-25.68% |
| 2022-12-31 | Nkr82.51 Million ≈ $8.68 Million |
-29.86% |
| 2021-12-31 | Nkr117.63 Million ≈ $12.38 Million |
-30.90% |
| 2020-12-31 | Nkr170.23 Million ≈ $17.91 Million |
+226.72% |
| 2019-12-31 | Nkr52.10 Million ≈ $5.48 Million |
-17.60% |
| 2018-12-31 | Nkr63.23 Million ≈ $6.65 Million |
+215.78% |
| 2017-12-31 | Nkr20.02 Million ≈ $2.11 Million |
-- |
About Exact Therapeutics AS
EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology and brain diseases. … Read more